iga

Documents about iga

• Study of the IgA Repertoire During IgA Deposition Nephropathy.#1113169ClinicalTrials.gov
• Atacicept in Multiple Glomerular Diseases#994779ClinicalTrials.gov
• IgA-positive Versus IgA-negative Immune Complex Vasculitis#1008300ClinicalTrials.gov
• A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy#832841ClinicalTrials.gov
• Effect of Immunosuppression in IgA Nephropathy#1171881ClinicalTrials.gov
• Probiotics in IgA Nephropathy#893908ClinicalTrials.gov
• Effect of Finerenone in IgA Nephropathy#1057353ClinicalTrials.gov
• A Study of Telitacicept for IgA Nephropathy (TELIGAN)#1093969ClinicalTrials.gov
• Rituximab in Recurrent IgA Nephropathy#1363700ClinicalTrials.gov
• Mediators of Loin Pain in IgA Nephropathy#852002ClinicalTrials.gov
• Diet Intervention in Food Sensitive Patients With IgA Nephropathy#1139947ClinicalTrials.gov
• The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease#811431ClinicalTrials.gov
• Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy#887263ClinicalTrials.gov
• Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy#833050ClinicalTrials.gov
• Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy#855538ClinicalTrials.gov
• Acthar on Proteinuria in IgA Nephropathy Patients#1397413ClinicalTrials.gov
• PS-002 for the Treatment of IgA Nephropathy in Adults#895528ClinicalTrials.gov
• Atrasentan in Patients With IgA Nephropathy#1294950ClinicalTrials.gov
• To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy#1085514ClinicalTrials.gov
• A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy#1411036ClinicalTrials.gov
• Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA Vasculitis#414391ClinicalTrials.gov
• The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)#872599ClinicalTrials.gov
• A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy#1033570ClinicalTrials.gov
• Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy#1451389ClinicalTrials.gov
• RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)#1497882ClinicalTrials.gov
• Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy#387258ClinicalTrials.gov
• Correlation of Microbiome and Metabonomics With IgA Nephropathy#1231292ClinicalTrials.gov
• Mycophenolate Mofetil for IgA Nephropathy#1410965ClinicalTrials.gov
• Baseline characteristics of the population-based cohort in Iga City - the Iga City Cohort Study#223941bioRxiv / medRxiv
• Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study#802070ClinicalTrials.gov
• Fecal Microbiota Transplantation for Refractory IgA Nephropathy#833142ClinicalTrials.gov
• A Trial of HRS-5965 Tablets in Primary IgA Nephropathy#982693ClinicalTrials.gov
• Registry of IgA Nephropathy in Chinese Children#1150022ClinicalTrials.gov
• Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy#1369303ClinicalTrials.gov
• Airway IgA: Respiratory Tract IgA Levels in Anesthetized Patients Undergoing Elective Surgical Procedures#1454010ClinicalTrials.gov
• A Controlled Study of Uric Acid on the Progression of IgA Nephropathy#1465992ClinicalTrials.gov
• Challenges in access to novel IgA nephropathy therapeutics in South Asia#1500313Europe PMC
• The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy#857467ClinicalTrials.gov
• Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy#871251ClinicalTrials.gov
• Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers#1009205ClinicalTrials.gov
• Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy#1138972ClinicalTrials.gov
• Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy#1349748ClinicalTrials.gov
• Pilot Study of Velcade® in IgA Nephropathy#802475ClinicalTrials.gov
• Study of the Link Between Complement Activation and IgA Nephropathy Severity#1437691ClinicalTrials.gov
• A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy#1454763ClinicalTrials.gov
• Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)#905241ClinicalTrials.gov
• Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD#803024ClinicalTrials.gov
• B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency#858054ClinicalTrials.gov
• Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy#871667ClinicalTrials.gov
• A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy#873477ClinicalTrials.gov